Chaozhi Bu
Overview
Explore the profile of Chaozhi Bu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
40
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cheng J, Bu C, Zheng X
Sci Rep
. 2025 Feb;
15(1):5260.
PMID: 39939393
Previous studies have reported that cardiorespiratory fitness (CRF) was associated with decreased risk of chronic kidney disease (CKD) in westerner. The aim of present study was to investigate the potential...
2.
Zhang L, Li J, Wan Q, Bu C, Jin W, Yuan F, et al.
Mol Cell Probes
. 2024 Dec;
79:101997.
PMID: 39645054
The therapeutic potential of intestinal stem cell-derived extracellular vesicles (ISCs-EVs) in necrotizing enterocolitis (NEC) remains largely unexplored. This research aims to investigate the therapeutic effects of ISCs-EVs on NEC. Lgr5-positive...
3.
Zhang L, Jin W, Hu M, Su Y, Zhang Y, Yuan F, et al.
Heliyon
. 2024 Sep;
10(17):e37087.
PMID: 39286078
Background: Necrotizing enterocolitis (NEC) is a condition characterized by acquired damage to the mucosal lining, predominantly affecting premature infants. Bioinformatics assessments uncovered a notable rise in miR-155-5p expression in the...
4.
Bu C, Hu M, Su Y, Yuan F, Zhang Y, Xia J, et al.
J Cell Mol Med
. 2024 Jul;
28(14):e18534.
PMID: 39031467
Intestinal dysbiosis is believed to play a role in the development of necrotizing enterocolitis (NEC). The efficacy of JNK-inhibitory peptide (CPJIP) in treating NEC was assessed. Treatment with CPJIP led...
5.
Wang Q, Bu C, Dai Q, Chen J, Zhang R, Zheng X, et al.
Adv Sci (Weinh)
. 2024 Mar;
11(18):e2309748.
PMID: 38460157
Pulmonary delivery of therapeutic agents has been considered the desirable administration route for local lung disease treatment. As the latest generation of therapeutic agents, nucleic acid has been gradually developed...
6.
Xia J, Bu C, Zhang B, Wang X, Chen Y, Li T
Mol Biol Rep
. 2023 Dec;
51(1):12.
PMID: 38085373
MicroRNAs (miRNAs) are short noncoding RNAs, approximately 20-24 nucleotides long that negatively regulate gene expression by either inhibiting translation or cleaving complementary mRNA to participate in various biological processes. Accumulating...
7.
Xia J, Xu D, Qin Y, Wan F, Ren Y, Bu C, et al.
Technol Cancer Res Treat
. 2023 Nov;
22:15330338231212309.
PMID: 37942522
The pathogenesis of leukemia is complex and there are no effective diagnostic and prognostic indicators. Previous studies showed that microRNA-22 (miR-22) has altered expression level in multiple leukemia subtypes, which...
8.
Chen Y, Zou P, Bu C, Jiang Q, Xue L, Bao J, et al.
Mol Biol Rep
. 2023 Aug;
50(10):8189-8199.
PMID: 37563526
Background: Placenta accreta spectrum (PAS) is mainly characterized by excessive invasion of the uterine muscle layer accompanied by a large number of foreign blood vessels, leading to severe bleeding during...
9.
Ling P, Tang L, Lin M, Bu C, Yin Y, Wang F, et al.
Mol Cell Endocrinol
. 2023 Apr;
568-569:111916.
PMID: 37031914
Previous studies have shown that HE4 cancer biomarker promoted cancer cell proliferation and tumor growth in mouse xenograft models. Interestingly, HE4 levels are significantly increased in the seminal plasma of...
10.
Xia J, Feng S, Zhou J, Zhang L, Shi D, Wang M, et al.
Med Oncol
. 2022 Dec;
40(1):44.
PMID: 36481875
Glycogen Synthase Kinase-3 (GSK-3) was recently implicated in the dysregulated biology of acute myeloid leukemia (AML). Low concentrations of GSK-3 inhibitors, SB216763 and BIO, suppressed the proliferation of AML cells...